Er ultram
Ultram(R) ODT, which is indicated for moderate to moderately severe pain, received FDA approval er ultram on May 5, 2005, and will be available in a 50mg dosage strength. Ortho-McNeil anticipates an early-2006 er ultram launch for Ultram(R) ER and Ultram(R) ODT. Includes Extended-Release and Orally Disintegrating Tablet Formulations; — Launch Under Ultram(R) Brand Names Planned for Early 2006; — Biovail Receives $60-Million Supply Prepayment; — Biovail’s Supply Price Reaches 37. 5% of Partner’s Net Selling Price Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that a subsidiary has entered into a supply agreement with Ortho-McNeil, Inc. , a Johnson & Johnson company, for the marketing and distribution of a once-daily, extended-release (ER) formulation and an orally disintegrating (ODT), immediate-release formulation of tramadol hydrochloride in the United States and Puerto Rico. Both Biovail and Ortho-McNeil retain an option to extend the co-promotion arrangement by mutual consent for additional two-year periods. Dysphagia and swallowing impairment is a common problem in populations of elderly and infirm patients with estimates of the disorder affecting 40-50% of patients in nursing home facilities frequently receiving medicated analgesia. "The ability to leverage the Ultram(R) name is a competitive advantage that should provide Ortho-McNeil’s world-class sales force, and Biovail’s specialty sales force, an opportunity to quickly establish a significant market position for Ultram(R) ER " Ultram(R) ER, which is indicated for moderate to moderately severe chronic pain, received FDA approval on September 8, 2005, and will be available in 100mg, 200mg and 300mg dosage strengths. Douglas Squires, Chief Executive er ultram officer of Biovail Corporation. The supply prices go up to 37. 5% of Ortho-McNeil’s net selling price, depending on the year of sale, peaking in er ultram 2007 and beyond. Because Cipher’s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. Both formulations have already been approved by the United States Food Er ultram and Drug Administration (FDA). To the extent any statements made er ultram in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements Statements made in this news er ultram release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or er ultram implied in such statements. The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States. Subject to er ultram final FDA approval for the trade names, the extended-release and immediate-release formulations of tramadol will be marketed in the U. We have based these forward-looking statements on our current expectations and projections about future events.